Description and Prognostic Evaluation of Four Biological Parameters of Blast Cells in Adult Acute Lymphoblastic Leukemia

Analysis of Four Biological Parameters at Diagnosis of Adult Acute Lymphoblastic Leukaemia: DNA Index, Percentage of Cells in S-Phase, CD45 Fluorescence Index, and Protein P16: Prognostic Study in Patients Enrolled in a Multicentric Trial

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00188084

Enrollment

400

Registered

2005-09-16

Start date

2003-11-30

Completion date

2005-09-30

Last updated

2005-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Acute Lymphoblastic Leukemia

Brief summary

Adult acute lymphoblastic leukemia treatment approaches relie on risk stratification, including cytogenetics. We want to study at diagnosis several blast cells parameters on frozen samples of GRAALL protocols enrolled patients: 1. A CD45-DNA double staining analysed by flow cytometry will allow mesurement for each blastic clone of DNA ploidy, percentage of cells in S-phase, CD45 fluorescence index. 2. The proteine P16 metabolic way, involved in cell cycle regulation, will be studied by Western Blot analysis. The comparison between these parameters, and main haematological data, will be followed by a prognostic analysis, based on blast corticosensibility in vivo, chimiosensibility, complete remission, and survival. Combination of the studied parameters will allow to appreciate a clonal diversity. This will help to predict, at diagnosis, high probability of resistance to treatment.

Interventions

PROCEDUREDNA Index

PROCEDURES-Phase%

PROCEDURECD45 expression

PROCEDUREP16 metabolic way

Study design

Observational model

DEFINED_POPULATION

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to 59 Years

Healthy volunteers

Inclusion criteria

* All GRAALL 2003 and 2005 enrolled patients with available frozen blast cells

Exclusion criteria

* None

Countries

France

Contacts

Primary ContactAgnès F CHASSEVENT, PhD

a.chassevent@unimedia.fr33-(0)2-41-35-27-00

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026